GMP-certified pharmaceutical manufacturing unit for sale in Tahliwal, Una, Himachal Pradesh — operated as Glauben Pharma, a 12,000 sq ft cGMP facility manufacturing tablets, capsules and syrups, asking price ₹6.5 crore. Details on certification, machinery, and investment are below.
Location: Tahliwal Industrial Area, Una, Himachal Pradesh
The unit sits at Phase III, Industrial Area Tahliwal, Tehsil Haroli, District Una, Himachal Pradesh — an established pharmaceutical manufacturing cluster within the wider HP industrial belt. The facility is roughly 115–120 km from Chandigarh, with Chandigarh International Airport the nearest major air link. A buyer inherits proximity to an existing base of ancillary suppliers, testing laboratories, and a skilled pharma workforce already operating in the cluster.
Certification & Regulatory Status
The facility is a cGMP-approved unit, licensed by the Drugs Control Authority, Dharamshala, Himachal Pradesh, to manufacture tablets, capsules and syrups under manufacturing licence nos. NNZ/22/***and MNZ/22/*** (Form 25 and Form 28 respectively). Facility design and quality systems are built around Schedule M requirements for premises, plant, and equipment as prescribed under Indian drug manufacturing regulation1 and follow the core principles set out in WHO good manufacturing practice guidance for pharmaceutical products.2
The plant manufactures across eight therapeutic categories — antibiotics, cardiac, anti-diabetic, anti-cold, analgesic, antioxidant, multivitamin, and antifungal formulations — in tablet, capsule, and syrup dosage forms. It runs with a team of 16, including dedicated Production, Quality Control, Quality Assurance, and Engineering staff, and an in-house water system with a 1,000 litre/hour purified-water generation capacity and a 2,000 litre overhead storage tank.
References
- Central Drugs Standard Control Organisation. Schedule M — Good Manufacturing Practices for Premises and Materials. Ministry of Health and Family Welfare, Government of India.
- World Health Organization. WHO good manufacturing practices for pharmaceutical products: main principles. WHO Technical Report Series.
Unique Features of Pharmaceutical Unit for Sale
This state-of-the-art pharmaceutical facility stands out with its advanced infrastructure, certifications, and strategic location. Below are the key details that make this unit an attractive investment:
- Land and Constructed Area: The unit has a total land area of 800 square yards, and a well-constructed area of 12,000 square feet, providing ample space for production and future expansion.
- Year of Establishment: The plant was installed in 2022, ensuring that the machinery and infrastructure are modern and aligned with the latest industry standards.
- Production Capacity: The unit can manufacture over 250 different formulations, including tablets, capsules, and syrups. It also offers third-party manufacturing to over 30 clients.
- Certifications: The facility is GMP certified, ensuring high-quality production processes and compliance with regulatory standards.
- Workforce: The plant is efficiently managed by a team of 30 experienced employees, ensuring smooth and uninterrupted operations.
- Business Model: The unit operates as a partnership entity and focuses on generic and ethical pharmaceuticals, catering to a wide market segment.
- EBITDA Margins: With margins ranging between 15-25%, the business is financially robust and offers significant profit potential.
Location of the Company is Strategically Important
The pharmaceutical unit is strategically located in Tahliwal of district Una, Himachal Pradesh, a state renowned for its investor-friendly policies and industrial incentives. The region offers benefits like:
- Tax Incentives: Himachal Pradesh provides several tax exemptions and subsidies for pharmaceutical businesses, making it a cost-effective location. ( Note: After GST application Tax benefits in the state are over)
- Proximity to Markets: The unit is well-connected to major markets in North India, it is just 60 KM from Mohali Pb., It ensures efficient supply chain management.
- Pollution-Free Environment: The pristine surroundings and clean air quality ensure a conducive environment for pharmaceutical manufacturing.
Significant Features of the Pharmaceutical Unit for Sale Una
| Feature | Details |
|---|---|
| Total Area | 800 square yards |
| Constructed Area | 12,000 sq. ft. |
| Certifications | GMP |
| Production Lines | Tablets, Capsules, and Syrups |
| Third-Party Manufacturing | 30 Parties |
| Year of Establishment | 2022 |
| Workforce | 30 Employees |
| Product Range | 250+ Formulations |
| EBITDA Margins | 15-25% |
Why Invest in This Pharmaceutical Unit?
- Immediate Operational Capability: With fully functional production lines and existing third-party contracts, the subject unit is ready to operate without requiring significant additional investment.
- Diverse Product Portfolio: The unit’s ability to manufacture over 250 formulations positions it as a versatile player in the pharmaceutical market.
- Future Growth Potential: The spacious land area and modern infrastructure provide opportunities for further expansion and diversification. The unit has a vacant plot surrounding it to expand manufacturing capacity or add new production lines.
- Regulatory Compliance: The GMP certification ensures adherence to the highest standards of quality and safety, boosting credibility in the market.
FAQ:
What are the certifications included?
The unit is GMP-certified, ensuring compliance with international quality standards.
What is the price range of the unit?
Price details are available upon inquiry. Contact us for personalized information.
What is the current production capacity?
The facility can manufacture over 250 formulations, including tablets, capsules, and syrups, the per day manufacturing capacity of the company is as follows: Tablets 5 lakhs, Capsules 3 lakhs, and Liquid Orals 10000 bottles.
